Login / Signup

Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.

Kaden K FujitaFeng YeDavid CollisterScott KlarenbachDavid J T CampbellDerek S ChewAmity E QuinnPaul RonksleyDarren Lau
Published in: Diabetes, obesity & metabolism (2023)
SGLT2is may prevent eGFR decline and reduce the risk of adverse kidney events in adults with diabetes and nil or non-severe albuminuria.
Keyphrases
  • type diabetes
  • cardiovascular disease
  • glycemic control
  • small cell lung cancer
  • early onset
  • skeletal muscle
  • adipose tissue
  • insulin resistance
  • adverse drug
  • electronic health record